IVAX SUB TEVA PHARMS
GenericsIVAX SUB TEVA PHARMS is a generic drug manufacturer focused on Cardiovascular, Immunology, Infectious Disease.
IVAX SUB TEVA PHARMS's Key Drugs
IVAX SUB TEVA PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
IVAX SUB TEVA PHARMS's Recent FDA Approvals
IVAX SUB TEVA PHARMS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
IVAX SUB TEVA PHARMS's Therapeutic Areas
IVAX SUB TEVA PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
IVAX SUB TEVA PHARMS's Top Competitors
IVAX SUB TEVA PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, PAI HOLDINGS PHARM, and BAUSCH AND LOMB INC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
IVAX SUB TEVA PHARMS Pipeline Snapshot
Active clinical trials for IVAX SUB TEVA PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1963-07-05
- Latest
- 2026-05-19
- Applications
- 176